Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy

European Journal of Endocrinology

Volumn 167, Issue 3, 2012, Pages 353-362

  Barbosa, Edna J L ^a,b   Glad, Camilla A M ^a,c   Nilsson, Anna G ^a   Nyström, Helena Filipsson ^a   Götherström, Galina ^a   Svensson, Per Arne ^c   Vinotti, Isabela ^b   Bengtsson, Bengt Åke ^a   Nilsson, Staffan ^d   Boguszewski, Cesar Luiz ^b   Johannsson, Gudmundur ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ADULT; ALLELE; APOB GENE; APOE GENE; ARTICLE; CETP GENE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE TITRATION; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PPARG GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DWARFISM, PITUITARY; FEMALE; GENETIC VARIATION; GENOTYPE; HUMAN GROWTH HORMONE; HUMANS; LIPID METABOLISM; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84865761174     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0263     Document Type: Article

References (42)

1. Abrams P & Abs R. The lipid profile in adult hypopituitary patients with growth hormone deficiency. In Growth Hormone Deficiency in Adults - 10 years of KIMS, 1st edn, ch 12, pp 127-138. Eds R Abs & U Feldt-Rasmussen. Oxford: Oxford PharmaGenesis Ltd., 2004.
2. Christ ER, Cummings MH, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Naoumova RP, Boroujerdi MA, Sönksen PH &Russell-Jones DL. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. Journal of Clinical Endocrinology and Metabolism 1999 84 307-316. (doi:10.1210/jc.84.1.307)
3. Barbosa EJL, Koranyi J, Filipsson H, Bengtsson B-Å, Boguszewski CL & Johannsson G. Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. European Journal of Endocrinology 2010 162 869-878. (doi:10.1530/EJE-09-0973)
4. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B &Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199. (doi:10.1210/jc.2003-030840)
5. Garry P, Collins P & Devlin JG. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. European Journal of Endocrinology 1996 134 61-66. (doi:10.1530/eje.0.1340061)
6. Leese GP, Wallymahmed M, VanHeyningen C, Tames F, Wieringa G & MacFarlane IA. HDL-cholesterol reductions associated with adult growth hormone replacement. Clinical Endocrinology 1998 49 673-677. (doi:10.1046/j.1365-2265. 1998.00597.x)
7. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rosen T, Thoren M & Bengtsson BA. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. Journal of Clinical Endocrinology and Metabolism 1996 81 1575-1581. (doi:10.1210/jc.81.4.1575)
8. Cook DM, Ludlam WH & Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1999 84 3956-3960. (doi:10.1210/jc.84.11.3956)
9. Boguszewski CL, Meister LH, Zaninelli DC & Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. European Journal of Endocrinology 2005 152 67-75. (doi:10.1530/eje.1.01817)
10. Jorge AA & Arnhold IJ. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment. Hormone Research 2009 71 (Suppl 2) 55-63. (doi:10.1159/000192438)
11. van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW & Romijn JA. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2008 93 2828-2834. (doi:10.1210/jc.2007-2728)
12. Giavoli C, Ferrante E, Profka E, Olgiati L, Bergamaschi S, Ronchi CL, Verrua E, Filopanti M, Passeri E, Montefusco L, Lania AG, Corbetta S, Arosio M, Ambrosi B, Spada A & Beck-Peccoz P. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. European Journal of Endocrinology 2010 163 361-368. (doi:10.1530/EJE-10-0317)
13. Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL & Johannsson G. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 2009 94 639-644. (doi:10.1210/jc.2008- 0323)
14. Moyes VJ, Walker DM, Owusu-Antwi S, Maher KT, Metherell L, Akker SA, Monson JP, Clark AJ & Drake WM. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults. Clinical Endocrinology 2010 72 807-813. (doi:10.1111/j.1365-2265.2009.03768.x)
15. Dullaart RPF, van den Berg G, van der Knaap AM, Dijck-Brouwer J, Dallinga-Thie GM, Zelissen PMJ, Sluiter WJ & van Beek AP. HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C>A) and modified by glucocorticoid treatment. European Journal of Endocrinology 2010 162 227-234. (doi:10.1530/EJE-09-0742)
16. Benn M, Stene MC, Nordestgaard BG, Jensen GB, Steffensen R &Tybjaerg-Hansen A. Common and rare alleles in apolipoprotein B contribute to plasma levels of low-density lipoprotein cholesterol in the general population. Journal of Clinical Endocrinology and Metabolism 2008 93 1038-1045. (doi:10.1210/jc.2007-1365)
17. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL & Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nature Genetics 2008 40 161-169. (doi:10.1038/ng.76)
18. Lamon-Fava S, Asztalos BF, Howard TD, Reboussin DM, Horvath KV, Schaefer EJ & Herrington DM. Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL sub-populations before and after hormone therapy in postmenopausal women. Clinical Endocrinology 2010 72 169-175. (doi:10.1111/j.1365-2265.2009.03644.x)
19. Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP & Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circulation. Cardiovascular Genetics 2009 2 26-33. (doi:10.1161/CIRCGENETICS.108.817304)
20. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE &Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. American Journal of Epidemiology 2002 155 487-495. (doi:10.1093/aje/155.6.487)
21. Klos K, Shimmin L, Ballantyne C, Boerwinkle E, Clark A, Coresh J, Hanis C, Liu K, Sayre S & Hixson J. APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Human Molecular Genetics 2008 17 2039-2046. (doi:10.1093/hmg/ddn101)
22. Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J & Amouyel P. A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 289-294. (doi:10.1161/01.ATV.0000051382.28752.FE)
23. Fernandes-Rosa FL, Bueno AC, de Souza RM, de Castro M, dos Santos JE, Foss MC, Zennaro MC, Bettiol H, Barbieri MA &Antonini SR. Mineralocorticoid receptor p.I180V polymorphism: association with body mass index and LDL-cholesterol levels. Journal of Endocrinological Investigation 2010 33 472-477.
24. Ho KKY. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology 2007 157 695-700. (doi:10.1530/EJE-07-0631)
25. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA & Bengtsson B-Å. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid and osteocalcin. Clinical Endocrinology 1994 41 351-357. (doi:10.1111/j.1365-2265.1994.tb02556.x)
26. Svensson J, Johannsson G & Bengtsson BA. Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clinical Endocrinology 1997 46 579-586. (doi:10.1046/j.1365-2265.1997.1851001.x)
27. Wiklund O, Fager G, Olofsson SO, Wilhelmsson C & Bondjers G. Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors - determination of apolipoprotein D. Atherosclerosis 1980 37 631-636. (doi:10.1016/0021-9150(80)90070-2)
28. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
29. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L & Bengtsson BA. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 2142-2150. (doi:10.1161/01.ATV.15.12.2142)
30. Johannsson G, Bengtsson BA, Andersson B, Isgaard J & Caidahl K. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clinical Endocrinology 1996 45 305-314. (doi:10.1046/j.1365-2265.1996.00820.x)
31. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G &Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. Journal of Clinical Endocrinology and Metabolism 2007 92 1442-1445. (doi:10.1210/jc.2006-1487)
32. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N &Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency, A randomized, controlled clinical trial. Annals of Internal Medicine 2000 133 111-122.
33. Weiss LA, Pan L, Abney M & Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nature Genetics 2006 38 218-222. (doi:10.1038/ng1726)
34. Bennet AM, Reynolds CA, Gatz M, Blennow K, Pedersen NL &Prince JA. Pleiotropy in the presence of allelic heterogeneity: alternative genetic models for the influence of APOE on serum LDL, CSF amyloid-b42, and dementia. Journal of Alzheimer's Disease 2010 22 129-134. (doi:10.3233/JAD-2010-100864)
35. Beekman M, Heijmans BT, Martin NG, Pedersen NL, Whitfield JB, Defaire U, van Baal GC, Snieder H, Vogler GP, Slagboom PE &Boomsma DI. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Research 2002 5 87-97. (doi:10.1375/1369052022956)
36. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS &Bork P. Prediction of deleterious human alleles. Human Molecular Genetics 2001 10 591-597. (doi:10.1093/hmg/10.6.591)
37. Ng PC & Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Research 2003 31 3812-3814. (doi:10.1093/nar/ gkg509)
38. Wojczynski MK, Gao G, Borecki I, Hopkins PN, Parnell L, Lai CQ, Ordovas JM, Chung BH & Arnett DK. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. Journal of Lipid Research 2010 51 3316-3323. (doi:10.1194/jlr.P001834)
39. Dachet C, Poirier O, Cambien F, Chapman J & Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 507-515. (doi:10.1161/01.ATV.20.2.507)
40. Thompson A, Di Angelantonio E, Sarwar N, Ergou S, Saleheen D, Dullaart RPF, Keavney B, Ye Z & Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. Journal of the American Medical Association 2008 299 2777-2788. (doi:10.1001/jama.299.23.2777)
41. Sarzynski MA, Jacobson P, Rankinen T, Carlsson B, Sjostrom L, Carlsson LM & Bouchard C. Association of GWAS-based candidate genes with HDL-cholesterol levels before and after bariatric surgery in the Swedish obese subjects study. Journal of Clinical Endocrinology and Metabolism 2011 96 E953-E957. (doi:10.1210/jc.2010-2227)
42. Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE & Hingorani AD. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. American Journal of Human Genetics 2009 85 628-642. (doi:10.1016/j.ajhg.2009.10.014)